Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
The bold, dynamic, and new logo unveiled in this process captures the essence of the 'Better Together' theme
Subscribe To Our Newsletter & Stay Updated
